Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges

[1]  Ramil Hakim,et al.  Spinal Cord Injury Induces Permanent Reprogramming of Microglia into a Disease-Associated State Which Contributes to Functional Recovery , 2021, The Journal of Neuroscience.

[2]  Jacob O Day,et al.  The Genetics of Parkinson’s Disease and Implications for Clinical Practice , 2021, Genes.

[3]  V. Karrenbauer,et al.  Chronic Immunosuppression and Potential Infection Risks in CSF1R‐Related Leukoencephalopathy , 2021, Movement disorders : official journal of the Movement Disorder Society.

[4]  Z. Wszolek,et al.  Genetics of Parkinson's disease in the Polish population. , 2021, Neurologia i neurochirurgia polska.

[5]  C. Theiss,et al.  Little Helpers or Mean Rogue—Role of Microglia in Animal Models of Amyotrophic Lateral Sclerosis , 2021, International journal of molecular sciences.

[6]  M. Higuchi,et al.  Microglial gene signature reveals loss of homeostatic microglia associated with neurodegeneration of Alzheimer’s disease , 2021, Acta Neuropathologica Communications.

[7]  J. Muñoz-García,et al.  The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis , 2021, Theranostics.

[8]  J. D. del Río,et al.  Macrophagic and microglial complexity after neuronal injury , 2020, Progress in Neurobiology.

[9]  P. Edison,et al.  Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? , 2020, Nature Reviews Neurology.

[10]  Z. Wszolek,et al.  Microglial replacement therapy: a potential therapeutic strategy for incurable CSF1R-related leukoencephalopathy , 2020, Acta neuropathologica communications.

[11]  P. Benkert,et al.  Accurate classification of secondary progression in multiple sclerosis using a decision tree , 2020, Multiple sclerosis.

[12]  R. Patani,et al.  The microglial component of amyotrophic lateral sclerosis , 2020, Brain : a journal of neurology.

[13]  M. Ryten,et al.  Heritability Enrichment Implicates Microglia in Parkinson’s Disease Pathogenesis , 2020, medRxiv.

[14]  Juan Carlos Ledesma,et al.  Can We Treat Neuroinflammation in Alzheimer’s Disease? , 2020, International journal of molecular sciences.

[15]  R. Reynolds,et al.  Intrathecal Inflammation in Progressive Multiple Sclerosis , 2020, International journal of molecular sciences.

[16]  K. Blomgren,et al.  Underestimated Peripheral Effects Following Pharmacological and Conditional Genetic Microglial Depletion , 2020, International journal of molecular sciences.

[17]  M. Peviani,et al.  Heterogeneity of Neuroinflammatory Responses in Amyotrophic Lateral Sclerosis: A Challenge or an Opportunity? , 2020, International journal of molecular sciences.

[18]  R. Faull,et al.  Identification of a dysfunctional microglial population in human Alzheimer’s disease cortex using novel single-cell histology image analysis , 2020, Acta neuropathologica communications.

[19]  D. Bohl,et al.  Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival , 2020, Nature Neuroscience.

[20]  L. Gan,et al.  A MAC2-positive progenitor-like microglial population is resistant to CSF1R inhibition in adult mouse brain , 2020, eLife.

[21]  O. Butovsky,et al.  CSF1R signaling is a regulator of pathogenesis in progressive MS , 2020, Cell Death & Disease.

[22]  S. Rivest,et al.  An Early Microglial Response Is Needed To Efficiently Control Herpes Simplex Virus Encephalitis , 2020, Journal of Virology.

[23]  Ukpong B. Eyo,et al.  Negative feedback control of neuronal activity by microglia , 2020, Nature.

[24]  D. Vavvas,et al.  CSF1R inhibition by a small-molecule inhibitor is not microglia specific; affecting hematopoiesis and the function of macrophages , 2020, Proceedings of the National Academy of Sciences.

[25]  M. Fang,et al.  Inhibited CSF1R Alleviates Ischemia Injury via Inhibition of Microglia M1 Polarization and NLRP3 Pathway , 2020, Neural plasticity.

[26]  J. Priller,et al.  Single-cell mass cytometry reveals complex myeloid cell composition in active lesions of progressive multiple sclerosis , 2020, Acta Neuropathologica Communications.

[27]  K. Green,et al.  To Kill a Microglia: A Case for CSF1R Inhibitors. , 2020, Trends in immunology.

[28]  J. Attems,et al.  Microglia depletion diminishes key elements of the leukotriene pathway in the brain of Alzheimer’s Disease mice , 2020, Acta Neuropathologica Communications.

[29]  Hyung-do Choi,et al.  Inhibition of Colony-Stimulating Factor 1 Receptor by PLX3397 Prevents Amyloid Beta Pathology and Rescues Dopaminergic Signaling in Aging 5xFAD Mice , 2020, International journal of molecular sciences.

[30]  H. van Essen,et al.  Pharmacological depletion of microglia and perivascular macrophages prevents Vascular Cognitive Impairment in Ang II-induced hypertension , 2020, Theranostics.

[31]  D. Dash,et al.  Therapeutic Update on Huntington’s Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies , 2020, Neurotherapeutics.

[32]  H. Gelderblom,et al.  Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor. , 2020, Future oncology.

[33]  C. Duyckaerts,et al.  Huntington’s disease alters human neurodevelopment , 2020, Science.

[34]  G. Landreth,et al.  Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies , 2020, Neurobiology of Disease.

[35]  T. E. Schultz,et al.  Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development , 2020, Drug design, development and therapy.

[36]  F. Tanaka,et al.  CCR2 is localized in microglia and neurons, as well as infiltrating monocytes, in the lumbar spinal cord of ALS mice , 2020, Molecular Brain.

[37]  M. Hafezparast,et al.  Potential of activated microglia as a source of dysregulated extracellular microRNAs contributing to neurodegeneration in amyotrophic lateral sclerosis , 2020, Journal of Neuroinflammation.

[38]  J. Jankovic,et al.  Parkinson disease and the immune system — associations, mechanisms and therapeutics , 2020, Nature Reviews Neurology.

[39]  D. Burke,et al.  A proposal for new diagnostic criteria for ALS , 2020, Clinical Neurophysiology.

[40]  C. Peer,et al.  Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib , 2020, Cancer Chemotherapy and Pharmacology.

[41]  G. Comi,et al.  The window of opportunity for treatment of progressive multiple sclerosis. , 2020, Current opinion in neurology.

[42]  M. Tremblay,et al.  Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington’s disease pathology , 2020, Journal of Neuroinflammation.

[43]  Alistair M. Glidden,et al.  Patient-reported impact of symptoms in Huntington disease , 2020, Neurology.

[44]  R. Dantzer,et al.  Microglia depletion fails to abrogate inflammation-induced sickness in mice and rats , 2020, Journal of Neuroinflammation.

[45]  R. Harris,et al.  Microglia depletion and alcohol: Transcriptome and behavioral profiles , 2020, Addiction biology.

[46]  V. Murthy,et al.  Microglial depletion disrupts normal functional development of adult-born neurons in the olfactory bulb , 2020, eLife.

[47]  S. Rose-John,et al.  Repopulating Microglia Promote Brain Repair in an IL-6-Dependent Manner , 2020, Cell.

[48]  S. Appel,et al.  Increased activation ability of monocytes from ALS patients , 2020, Experimental Neurology.

[49]  K. Kang,et al.  Evaluation of the Neuroprotective Effect of Microglial Depletion by CSF-1R Inhibition in a Parkinson’s Animal Model , 2020, Molecular Imaging and Biology.

[50]  Qiang Liu,et al.  Depletion of microglia in developing cortical circuits reveals its critical role in glutamatergic synapse development, functional connectivity, and critical period plasticity , 2020, Journal of neuroscience research.

[51]  M. Fukushima,et al.  Clinical Utility of the Pathogenesis-Related Proteins in Alzheimer’s Disease , 2020, International journal of molecular sciences.

[52]  M. Caligiuri,et al.  CSF1R inhibitor PLX5622 and environmental enrichment additively improve metabolic outcomes in middle-aged female mice , 2020, Aging.

[53]  T. Hata,et al.  Pharmacological Properties of JTE-952, an Orally Available and Selective Colony Stimulating Factor 1 Receptor Kinase Inhibitor. , 2020, Biological & pharmaceutical bulletin.

[54]  J. Christman,et al.  Colony‐stimulating factor 1 and its receptor are new potential therapeutic targets for allergic asthma , 2020, Allergy.

[55]  Guo-Yuan Yang,et al.  Microglia exacerbate white matter injury via complement C3/C3aR pathway after hypoperfusion , 2020, Theranostics.

[56]  Qi Zhou,et al.  Nicotinamide Riboside Enhances Mitochondrial Proteostasis and Adult Neurogenesis through Activation of Mitochondrial Unfolded Protein Response Signaling in the Brain of ALS SOD1G93A Mice , 2020, International journal of biological sciences.

[57]  B. Becher,et al.  Microglial homeostasis requires balanced CSF-1/CSF-2 receptor signaling , 2019, bioRxiv.

[58]  L. Thompson,et al.  Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease. , 2019, Brain : a journal of neurology.

[59]  Xu Wang,et al.  Pharmacological Targeting of Microglial Activation: New Therapeutic Approach , 2019, Front. Cell. Neurosci..

[60]  F. Sellebjerg,et al.  Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease , 2019, Annals of neurology.

[61]  Helmut Kettenmann,et al.  Cien Años de Microglía: Milestones in a Century of Microglial Research , 2019, Trends in Neurosciences.

[62]  R. Faull,et al.  The Role of Microglia and Astrocytes in Huntington’s Disease , 2019, Front. Mol. Neurosci..

[63]  K. Elenitoba-Johnson,et al.  Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability , 2019, Clinical Cancer Research.

[64]  D. Holtzman,et al.  Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model , 2019, The Journal of experimental medicine.

[65]  Steffen Jung,et al.  Microglia Biology: One Century of Evolving Concepts , 2019, Cell.

[66]  A. Zarrin,et al.  CSF1R Ligands IL-34 and CSF1 Are Differentially Required for Microglia Development and Maintenance in White and Gray Matter Brain Regions , 2019, Front. Immunol..

[67]  W. Gomes-Leal.  Why microglia kill neurons after neural disorders? The friendly fire hypothesis , 2019, Neural regeneration research.

[68]  A. Lang,et al.  Parkinson's disease in the Western Pacific Region , 2019, The Lancet Neurology.

[69]  Caleb Webber,et al.  CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice , 2019, Brain : a journal of neurology.

[70]  Chao Zhang,et al.  Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model , 2019, Nature Communications.

[71]  David M. Thomas,et al.  Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial , 2019, The Lancet.

[72]  Ukpong B. Eyo,et al.  Microglia: Lifelong patrolling immune cells of the brain , 2019, Progress in Neurobiology.

[73]  J. Bennett,et al.  Concentration-dependent effects of CSF1R inhibitors on oligodendrocyte progenitor cells ex vivo and in vivo , 2019, Experimental Neurology.

[74]  F. Ginhoux,et al.  CSF-1 controls cerebellar microglia and is required for motor function and social interaction , 2019, The Journal of experimental medicine.

[75]  V. Miron,et al.  The pro-remyelination properties of microglia in the central nervous system , 2019, Nature Reviews Neurology.

[76]  K. Mortezaee,et al.  Effect of the CSF1R inhibitor PLX3397 on remyelination of corpus callosum in a cuprizone‐induced demyelination mouse model , 2019, Journal of cellular biochemistry.

[77]  Jane S. Paulsen,et al.  Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntington’s Disease , 2019, Biological Psychiatry.

[78]  Jeroen A. A. Demmers,et al.  Homozygous Mutations in CSF1R Cause a Pediatric-Onset Leukoencephalopathy and Can Result in Congenital Absence of Microglia. , 2019, American journal of human genetics.

[79]  Marjorie E. Adams,et al.  Targeting , 2019, Systems Engineering for Ethical Autonomous Systems.

[80]  M. Cookson,et al.  Glial phagocytic clearance in Parkinson’s disease , 2019, Molecular neurodegeneration.

[81]  P. Shepherd,et al.  The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice , 2019, International Journal of Obesity.

[82]  D. J. Doty,et al.  Microglial cell depletion is fatal with low level picornavirus infection of the central nervous system , 2019, Journal of NeuroVirology.

[83]  Ukpong B. Eyo,et al.  Neuronal network activity controls microglial process surveillance in awake mice via norepinephrine signaling , 2019, bioRxiv.

[84]  Shihua Li,et al.  Use of large animal models to investigate Huntington's diseases , 2019, Cell regeneration.

[85]  M. Prinz,et al.  Microglia in Central Nervous System Inflammation and Multiple Sclerosis Pathology. , 2019, Trends in molecular medicine.

[86]  S. Appel,et al.  Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies , 2019, The Lancet Neurology.

[87]  H. Lassmann.  Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis , 2019, Front. Immunol..

[88]  N. Fitz,et al.  The Role of APOE and TREM2 in Alzheimer′s Disease—Current Understanding and Perspectives , 2018, International journal of molecular sciences.

[89]  B. West,et al.  Targeting microglia attenuates neuroinflammation‐related neural damage in mice carrying human PLP1 mutations , 2018, Glia.

[90]  Alison J. Clare,et al.  Transcriptome Profiling of Layer 5 Intratelencephalic Projection Neurons From the Mature Mouse Motor Cortex , 2018, Front. Mol. Neurosci..

[91]  B. Hyman,et al.  Partial reduction of microglia does not affect tau pathology in aged mice , 2018, Journal of Neuroinflammation.

[92]  H. Weiner,et al.  Acute microglia ablation induces neurodegeneration in the somatosensory system , 2018, Nature Communications.

[93]  R. Harris,et al.  Enforced microglial depletion and repopulation as a promising strategy for the treatment of neurological disorders , 2018, Glia.

[94]  H. Noristani,et al.  CSF1R Inhibition Reduces Microglia Proliferation, Promotes Tissue Preservation and Improves Motor Recovery After Spinal Cord Injury , 2018, Front. Cell. Neurosci..

[95]  A. Najafi,et al.  Replacement of microglia in the aged brain reverses cognitive, synaptic, and neuronal deficits in mice , 2018, Aging cell.

[96]  D. Kurrasch,et al.  Depletion of embryonic microglia using the CSF1R inhibitor PLX5622 has adverse sex-specific effects on mice, including accelerated weight gain, hyperactivity and anxiolytic-like behaviour , 2018, Brain, Behavior, and Immunity.

[97]  S. Tsirka,et al.  Csf1R inhibition attenuates experimental autoimmune encephalomyelitis and promotes recovery , 2018, Experimental Neurology.

[98]  M. Tremblay,et al.  Microglial Implication in Parkinson’s Disease: Loss of Beneficial Physiological Roles or Gain of Inflammatory Functions? , 2018, Front. Cell. Neurosci..

[99]  E. Hjorth,et al.  Therapeutic Advances in Neurological Disorders , 2018 .

[100]  J. Attems,et al.  Phosphorylation of different tau sites during progression of Alzheimer’s disease , 2018, Acta Neuropathologica Communications.

[101]  Joseph R. Scarpa,et al.  Epigenetic regulation of brain region-specific microglia clearance activity , 2018, Nature Neuroscience.

[102]  B. Chesebro,et al.  Microglia Are Critical in Host Defense against Prion Disease , 2018, Journal of Virology.

[103]  Shihua Li,et al.  A Huntingtin Knockin Pig Model Recapitulates Features of Selective Neurodegeneration in Huntington’s Disease , 2018, Cell.

[104]  F. LaFerla,et al.  Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease , 2018, Molecular Neurodegeneration.

[105]  S. Perlman,et al.  Microglia are required for protection against lethal coronavirus encephalitis in mice , 2018, The Journal of clinical investigation.

[106]  Bo Peng,et al.  Repopulated microglia are solely derived from the proliferation of residual microglia after acute depletion , 2018, Nature Neuroscience.

[107]  E. Giorgetti,et al.  Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945 , 2018, Acta neuropathologica communications.

[108]  F. Shi,et al.  Depletion of microglia augments the dopaminergic neurotoxicity of MPTP , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[109]  Melanie A. Huntley,et al.  Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer's Disease Not Evident in Mouse Models. , 2018, Cell reports.

[110]  A. Regev,et al.  Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution , 2017, Cell reports.

[111]  Markus Glatzel,et al.  The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. , 2017, Immunity.

[112]  C. Wattmo,et al.  Early- versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years , 2017, Alzheimer's Research & Therapy.

[113]  Jia Liu,et al.  Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications , 2017, Front. Immunol..

[114]  F. Michetti,et al.  The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches , 2017, Front. Aging Neurosci..

[115]  K. Cosgrove,et al.  Microglial depletion and activation: A [11C]PBR28 PET study in nonhuman primates , 2017, EJNMMI Research.

[116]  M. Prinz,et al.  Microglia contribute to normal myelinogenesis and to oligodendrocyte progenitor maintenance during adulthood , 2017, Acta Neuropathologica.

[117]  P. Shaw,et al.  The role of mitochondria in amyotrophic lateral sclerosis , 2017, Neuroscience Letters.

[118]  R. Harris,et al.  An updated assessment of microglia depletion: current concepts and future directions , 2017, Molecular Brain.

[119]  B. Tang,et al.  Microglial Activation in the Pathogenesis of Huntington’s Disease , 2017, Front. Aging Neurosci..

[120]  I. Amit,et al.  A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease , 2017, Cell.

[121]  H. Federoff,et al.  Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease , 2017, Front. Aging Neurosci..

[122]  T. Jin,et al.  Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications , 2017, Journal of neuroscience research.

[123]  R. Perlis,et al.  Patient-specific models of microglia-mediated engulfment of synapses and neural progenitors , 2016, Molecular psychiatry.

[124]  Sung Hoon Baik,et al.  Microglia contributes to plaque growth by cell death due to uptake of amyloid β in the brain of Alzheimer's disease mouse model , 2016, Glia.

[125]  W. Le,et al.  Protective Microglia and Their Regulation in Parkinson’s Disease , 2016, Front. Mol. Neurosci..

[126]  M. Mehler,et al.  Emerging Roles for CSF-1 Receptor and its Ligands in the Nervous System , 2016, Trends in Neurosciences.

[127]  V. Perry,et al.  CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves , 2016, Scientific Reports.

[128]  M. Prados,et al.  Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. , 2016, Neuro-oncology.

[129]  A. Najafi,et al.  Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology. , 2016, Brain : a journal of neurology.

[130]  B. Stevens,et al.  New insights on the role of microglia in synaptic pruning in health and disease , 2016, Current Opinion in Neurobiology.

[131]  S. Pappatà,et al.  Imaging of brain TSPO expression in a mouse model of amyotrophic lateral sclerosis with 18F-DPA-714 and micro-PET/CT , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[132]  Mariana Vargas-Caballero,et al.  Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology , 2016, Brain : a journal of neurology.

[133]  F. Turkheimer,et al.  Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers , 2015, Neurobiology of Disease.

[134]  Jennifer Luebke,et al.  Depletion of microglia and inhibition of exosome synthesis halt tau propagation , 2015, Nature Neuroscience.

[135]  B. MacVicar,et al.  Microglia: Dynamic Mediators of Synapse Development and Plasticity. , 2015, Trends in immunology.

[136]  A. Najafi,et al.  Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice , 2015, Journal of Neuroinflammation.

[137]  M. van de Rijn,et al.  Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. , 2015, The New England journal of medicine.

[138]  J. Palmblad,et al.  Resolution of inflammation is altered in Alzheimer's disease , 2015, Alzheimer's & Dementia.

[139]  E. Stanley,et al.  CSF-1 receptor signaling in myeloid cells. , 2014, Cold Spring Harbor perspectives in biology.

[140]  J. Koistinaho,et al.  The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis , 2014, Front. Cell. Neurosci..

[141]  C. Putterman,et al.  Macrophage depletion ameliorates nephritis induced by pathogenic antibodies. , 2015, Journal of autoimmunity.

[142]  Brian L. West,et al.  Colony-Stimulating Factor 1 Receptor Signaling Is Necessary for Microglia Viability, Unmasking a Microglia Progenitor Cell in the Adult Brain , 2014, Neuron.

[143]  M. Mehler,et al.  Receptor-type Protein-tyrosine Phosphatase ζ Is a Functional Receptor for Interleukin-34* , 2013, The Journal of Biological Chemistry.

[144]  J. Relton,et al.  Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival , 2013, The Journal of experimental medicine.

[145]  R. Vassar,et al.  Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation , 2013, Molecular Neurodegeneration.

[146]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[147]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[148]  F. Ginhoux,et al.  Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia. , 2012, Immunity.

[149]  V. Nacu,et al.  Pstpip2 Deficiency in Mice Causes Osteopenia and Increased Differentiation of Multipotent Myeloid Precursors into Osteoclasts Serum Levels of the Pro-osteoclastogenic Factor, Mip-1␣, Were Elevated and Csf-1 Receptor (csf-1r)–dependent Produc- Tion of Mip-1␣ by Macrophages Was In- Creased. Treatment , 2022 .

[150]  M. Diamond,et al.  IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia , 2012, Nature Immunology.

[151]  Oliver Wirths,et al.  Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease , 2012, Neurobiology of Aging.

[152]  J. Pollard,et al.  Absence of Colony Stimulation Factor-1 Receptor Results in Loss of Microglia, Disrupted Brain Development and Olfactory Deficits , 2011, PloS one.

[153]  O. Crespo,et al.  Tyrosine Kinase Inhibitors Ameliorate Autoimmune Encephalomyelitis in a Mouse Model of Multiple Sclerosis , 2011, Journal of Clinical Immunology.

[154]  R. Roos,et al.  Huntington's disease: a clinical review , 2010, Orphanet journal of rare diseases.

[155]  F. Ginhoux,et al.  Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages , 2010, Science.

[156]  I. Duncan,et al.  Selective reduction in microglia density and function in the white matter of colony‐stimulating factor‐1–deficient mice , 2009, Journal of neuroscience research.

[157]  J. Bachevalier,et al.  Towards a transgenic model of Huntington’s disease in a non-human primate , 2008, Nature.

[158]  W Poewe,et al.  Non‐motor symptoms in Parkinson’s disease , 2008, European journal of neurology.

[159]  Isao Serizawa,et al.  The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis , 2008, Journal of Neuroimmunology.

[160]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[161]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[162]  J. Parham,et al.  Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[163]  Helen Neale,et al.  Modulation of CSF-1-regulated post-natal development with anti-CSF-1 antibody. , 2005, Immunobiology.

[164]  E. Yoshikawa,et al.  Microglial activation and dopamine terminal loss in early Parkinson's disease , 2005, Annals of neurology.

[165]  J. Murray,et al.  Mechanism of phosphatidylinositol 3-kinase-dependent increases in BAC1.2F5 macrophage-like cell density in response to M-CSF: Phosphatidylinositol 3-kinase inhibitors increase the rate of apoptosis rather than inhibit DNA synthesis , 2000, Inflammation Research.

[166]  L. Shultz,et al.  Effects of macrophage‐colony‐stimulating factor deficiency on the maturation of microglia and brain macrophages and on their expression of scavenger receptor , 2000, Neuropathology : official journal of the Japanese Society of Neuropathology.

[167]  Michael C. Ostrowski,et al.  Macrophage Colony-stimulating Factor Promotes Cell Survival through Akt/Protein Kinase B* , 1999, The Journal of Biological Chemistry.

[168]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[169]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[170]  E. Stern,et al.  Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study. , 2019, Neurology(R) neuroimmunology & neuroinflammation.

[171]  C. Ries,et al.  Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. , 2017, Journal for immunotherapy of cancer.

[172]  E. Stanley,et al.  Regulation of Embryonic and Postnatal Development by the CSF-1 Receptor. , 2017, Current topics in developmental biology.